Amicus Therapeutics, Inc.

Amicus Therapeutics Misses on Revenue, Stock Down 1.17%

Amicus Therapeutics reported a narrower loss per share than expected, which is a positive sign for investors. However, the lack of revenue figures and guidance may raise concerns about future performance. The stock reacted negatively, declining by 1.17%, likely due to uncertainty surrounding revenue generation and future outlook.